New data, including two late-breaking clinical trial presentations on mavacamten and a new analysis of the GUARD-AF study, reinforce the company’s continued commitment to those living with cardiovascular disease
Cardiovascular disease is the leading cause of death in the Asia Pacific, and it's a problem that will only intensify as populations continue to age
One of the key factors driving the market growth is the rise in the occurrence of chronic cardiovascular diseases such as heart failure and coronary artery disease: Valuates Reports
The Chennai facility will manufacture high-quality medical tubing for neurovascular and cardiovascular applications, including balloon catheters and other minimally invasive devices
The partnership initially will focus on cardiovascular and kidney diseases
Myqorzo, a selective small-molecule cardiac myosin inhibitor, is designed to improve functional capacity and relieve symptoms in oHCM
The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle
Penumbra projects fourth-quarter revenue growth of 21.4% to 22.0%, with full-year 2025 revenue expected to reach approximately $1.4 billion
The deal to acquire AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) underscores Bayer’s commitment to expanding in molecular imaging and advancing precision cardiology
The acquisition of AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) positions Bayer at the forefront of cardiac amyloidosis diagnostics
Subscribe To Our Newsletter & Stay Updated
